Fig. 3From: Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy12/2019 T2 and FLAIR images. MRI after switch to ocrelizumab. Almost complete regression of inratentorial RS lesions. Supratentorial lesions without progressionBack to article page